INZY — Inozyme Pharma Income Statement
0.000.00%
Last trade - 00:00
- $274.27m
- $130.45m
- 44
- 24
- 72
- 44
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 20.8 | 57 | 56.6 | 68.7 | 75.6 |
Operating Profit | -20.8 | -57 | -56.6 | -68.7 | -75.6 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -19.7 | -56.4 | -56.6 | -67.1 | -71.2 |
Net Income After Taxes | -19.7 | -56.4 | -56.6 | -67.1 | -71.2 |
Net Income Before Extraordinary Items | |||||
Net Income | -19.7 | -56.4 | -56.6 | -67.1 | -71.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -19.7 | -56.4 | -56.6 | -67.1 | -71.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.971 | -2.41 | -2.4 | -1.78 | -1.37 |
Dividends per Share |